Akero Therapeutics, Inc.

Equities

AKRO

US00973Y1082

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 10:10:52 2024-03-28 am EDT 5-day change 1st Jan Change
23.88 USD -2.33% Intraday chart for Akero Therapeutics, Inc. -8.06% +2.14%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Akero Therapeutics Raises $367 Million From Share Offering MT
Akero Therapeutics, Inc. Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology CI
Akero Therapeutics Insider Sold Shares Worth $732,727, According to a Recent SEC Filing MT
Akero Therapeutics Insider Sold Shares Worth $2,465,063, According to a Recent SEC Filing MT
UBS Adjusts Akero Therapeutics Price Target to $42 From $39, Maintains Buy Rating MT
HC Wainwright Raises Price Target on Akero Therapeutics to $50 From $43, Maintains Buy Rating MT
Health Care Down on Growth Doubts -- Health Care Roundup DJ
Akero Therapeutics Proposes $300 Million Common Stock Offering -- Stock Down After Hours MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday MT
Sector Update: Health Care MT
US Equity Futures Turn Cautiously Lower Pre-Bell as Investors Eye Powell Testimony MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell as Traders Hope for Clues to Timing of Rate Cuts MT
Top Premarket Gainers MT
Transcript : Akero Therapeutics, Inc. - Special Call
Akero Therapeutics Reports Greater Fibrosis Improvement in Efruxifermin Phase 2b Study; Shares Gain Pre-Bell MT
Akero's lead drug helps improve scarring in fatty liver disease patients RE
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study CI
Akero Therapeutics' Q4 Loss Widens; Cash Expected to Fund Operations Into 2026 MT
Akero Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Akero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Transcript : Akero Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 09:45 AM
Akero Therapeutics, Inc. Announces First Patients Dosed in Efruxifermin Phase 3 Synchrony Program CI
Akero Therapeutics Insider Bought Shares Worth $1,982,940, According to a Recent SEC Filing MT
Akero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
UBS Adjusts Akero Therapeutics Price Target to $39 From $83, Maintains Buy Rating MT
Chart Akero Therapeutics, Inc.
More charts
Akero Therapeutics, Inc. is a clinical-stage company that develops transformational treatments for patients with serious metabolic diseases. The Company is engaged to treat non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. The Company's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. EFX is being evaluated in two Phase 2b clinical trials in patients with biopsy-confirmed NASH: a long-term follow-up period for the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), for which it reported results after 24 weeks of treatment, and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). Its EFX program focused on patients with cirrhotic NASH (F4, compensated), in Phase 2b clinical trial.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
24.45 USD
Average target price
51.25 USD
Spread / Average Target
+109.61%
Consensus